Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06335966 · ClinicalTrials.gov registry record
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
A clinical trial of Esophageal Cancer, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT06335966: Active study of Esophageal Cancer, sponsored by OHSU Knight Cancer Institute.
NCT06335966 is a study of Esophageal Cancer that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 110 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06335966, a study of Esophageal Cancer, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon.
Primary Outcome
Feasibility of screening for esophageal cancer via SECD in rural primary care settings will be measured by data collected from Provider Post-Inservice Questionnaire, which includes, Indication of provider likelihood of using SECD as a screening tool.
Conditions Studied
Interventions
- DEVICE Screening with swallowable esophageal cell-collection devices (SECD)
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-12-30 |
What the registry record for NCT06335966 still lists
NCT06335966 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Screening with swallowable esophageal cell-collection devices (SECD) is the first listed.
NCT06335966 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06335966 about?
NCT06335966 is a clinical study titled "BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy". Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and feasibility of using this novel...
What is the current status of trial NCT06335966?
This trial is currently active not recruiting. The enrollment target is 110 participants. The study started on 2024-09-11. Estimated completion is 2026-12-30.
What conditions does trial NCT06335966 study?
This clinical trial studies the following conditions: Esophageal Cancer.
What interventions are being tested in trial NCT06335966?
The interventions under investigation include: Screening with swallowable esophageal cell-collection devices (SECD) (DEVICE).
Who is sponsoring clinical trial NCT06335966?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06335966 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06335966's enrollment target sits among peer trials
110 50th of 123 higher than 74 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI